One of the unusual patterns of local recurrence in breast cancer patient is an inflammatory skin recurrence (ISR) sharply demarcating the area of previous radiation fields. To clarify the characteristics of this recurrence, we conducted a nationwide survey. We sent a survey to radiation oncologists at 200 institutions in Japan and received answers from 92. Of these, 24 institutions had some experience with patients who developed ISR affecting the previously irradiated area. The case details of 16 patients from 11 institutions were available and analyzed in this study. Eight patients experienced ISR after breast conservative therapy (groupA) and 8 patients experienced ISR after post-mastectomy radiotherapy (groupB). The postoperative pathological examination of groups A and B showed positive axillary lymph-nodes in 7/8 and 8/8 patients, positive lymphatic invasion in 4/7 and 7/8 patients, and ER status negative in 7/8 and 6/7 patients respectively. Median survival period was 266 days in groupA and 1105 days in groupB (p = 0.0001). Patients who developed the ISR tended to have several characteristics, including positive lymph-node metastases, intensive lymphatic invasion, and ER status negative. Physicians should contemplate the diagnosis of ISR next to radiation recall or radiation dermatitis, especially when the aforementioned risk factors are present.
INTRODUCTION
Loco-regional recurrences are common in patients with breast cancer who have been treated by breast conserving therapy (BCT) or radical mastectomy (RM). [1] [2] [3] An unusual pattern observed with loco-regional recurrence is inflammatory skin recurrence (ISR), also known as carcinoma erysipeloides, 4) characterized by cutaneous metastatic carcinoma with lymphatic involvement. It sometimes occurs exactly and sharply matched to the area of previous postoperative irradiation and it mimics radiation dermatitis or radiation recall phenomenon. Postoperative radiotherapy appears to facilitate tumor recurrence in the area of previously irradiated skin. However, the mechanism and the characteristics of this recurrence are not well understood. We therefore conducted a nationwide survey to study the characteristics and prognoses of breast cancer patients with ISR corresponding to the previously irradiated area.
MATERIALS AND METHODS
Surveys regarding experiences with ISR corresponding to the previous radiation fields after BCT or postmastectomy radiotherapy (PMRT) were sent in February 2006 to radiation oncologists of the Japanese Society for Therapeutic Radiology and Oncology working at 200 certified institutes in Japan. Ninety-two institutes (46%) returned the completed questionnaires. Of these, 24 institutes (26%) had some experiences with patients who had experienced ISR affecting the previously irradiated fields.
A second survey was sent to these 24 institutions regarding the characteristics and clinical courses of each patient. Of these, case details of 16 patients from 11 institutes were available. These 16 patients were analyzed in this study. All patients' information was submitted anonymously. After discussion between the authors, a third survey was sent later to the 11 institutions regarding population parameters of breast cancer patients treated with postoperative radiotherapy to estimate the approximate incidence of ISR. Because different time periods were used for the population parameters in the patient database of each institute, the third survey requested data regarding numbers of breast cancer patients treated with postoperative radiotherapy at each facility over the period from the oldest available year considered appropriate till 2005. The cumulative survival period was calculated using the Kaplan-Meier method and examined by the log-rank test (Dr. SPSS II, SPSS Japan).
RESULTS

Eight patients experienced ISR after BCT (group A) and another 8 patients experienced ISR after PMRT (group B).
Patient characteristics and postoperative pathology
Patient characteristics and postoperative pathological findings for the 8 patients in group A are summarized in Table 1 . The age of the patients ranged from 42 to 86 (median, 61) years old. The postoperative histology showed positive axillary lymph nodes in 7 of 8 patients (more than 4 nodes in 4 of 8 patients), positive lymphatic invasion in 4 of 7 patients (extensive invasion in 3 of 7), negative ER status in 7 of 8 patients, and close or positive surgical margins in 3 of 8 patients. Postoperative radiotherapy was delivered to the conserved breast only in 5 of 8 patients, and to both supraclavicular region and breast in 3 of 8 patients. Adjuvant or neo-adjuvant chemotherapy was administered in 6 of 8 patients.
The group B patient characteristics and postoperative pathological findings are given in Table 2 . Ages ranged from 38 to 67 (median, 56) years old. The postoperative histology showed positive axillary lymphnodes in 8 of 8 patients (more than 4 nodes in 5 of 8 patients), positive lymphatic invasion in 7 of 8 patients (extensive invasion in 4 of 8), negative ER status in 6 of 7 patients, and close or positive margin in 1 of 8 patients. Postoperative radiotherapy was delivered to the chest wall and supraclavicular region in 5 of 8 patients, chest wall only in 1 of 8 patients and chest wall, supraclavicular region, and internal mammary region in 2 of 8 patients. Adjuvant or neoadjuvant chemotherapy were administered to 8 of 8 patients.
Clinical courses
The clinical courses of group A patients are summarized in Table 3 . The time periods between the completion of radiotherapy and ISR were ranged from 1 to 27 months (median, 3.5 months). Pathological confirmation of the inflammatory recurrent site was performed in 6 of 8 patients. ISR was the initial solitary site of recurrence after postoperative radiotherapy in 3 of 8 patients. Two patients developed inflammatory local recurrence and regional lymph-nodes or lung metastases simultaneously. Three other patients had preceding distant metastases. All 8 patients in group A subsequently developed distant metastases and died of disease in 3-16 months.
The group B patient clinical courses are summarized in Table 4 . The time periods between the completion of radiotherapy and the occurrence of ISR ranged from 2 to 33 Median survival periods were 8.9 months in group A and 36.8 months in group B (p = 0.0001).
Estimation of the incidence of ISR
Ten out of 11 institutes completed the third survey. The total number of patients treated with postoperative radiotherapy for breast cancer at these 10 institutes between 1992 and 2005 (initial year was different in each institute, ranging from 1992 to 2001) was 6061. From these 10 institutes, 15 patients were enrolled in this study. Thus, estimation of the incidence of ISR affecting the previous radiation fields after BCT or PMRT was considered to be approximately 0.25% (15/6061). Abbreviations: IDC = invasive ductal carcinoma, ly = lymphatic invasion, v = vascular invasion, br = breast, sc = supraclavicular, cw = chest wall, sc = supracalvicular, im = internal mammary, Cx = chemotherapy, Ex = endocrine therapy. Abbreviations: ISR = inflammatory skin recurrence, rec = recurrence, Cx = chemotherapy, Ex = endocrine therapy, RT = radiotherapy, HT = hyperthermia, LN = lymphnode, DOD = died of disease, AWD = alive with disease.
Case presentation
Case No.6: A 54-year-old postmenopausal woman who was diagnosed with cT2N1M0 right breast cancer and underwent neoadjuvant chemotherapy consisting of 4 courses of cyclophosphamide, epirubicin, fluorouracil and 4 courses of docetaxel followed by quadrantectomy and axillary dissection. Postoperative pathology showed an invasive ductal carcinoma (16 mm) of nuclear grade 3, a massive lymphatic invasion, and a close surgical margin. ER and PR status were negative and Her2 status was positive. Axillary lymph-nodes were positive for 23 out of 31 nodes. Postoperative radiotherapy of 50 Gy/25 fr by 60 Co was delivered to the right breast and right supraclavicular region. Three months after the completion of radiotherapy, ISR sharply matched to the area of previous irradiation fields was observed (Fig. 2) . Skin biopsy revealed the same histology as the primary breast cancer in the dermal collagen tissue. Salvage chemo-endocrine therapy was administered including trastuzumab and capecitabine. However, multiple lung metastases and mediastinal lymph-node metastases developed 6 months after the completion of radiotherapy. The patient died of disease 1 year after radiotherapy without responding to the additional chemotherapy, including paclitaxel and vinorelbine.
Case No.9: A 67-year-old postmenopausal woman diagnosed with cT1cN0M0 invasive ductal carcinoma of the left breast. She underwent a modified RM. Pathology revealed Abbreviations: ISR = inflammatory skin recurrence, rec = recurrence, Cx = chemotherapy, Ex = endocrine therapy, RT = radiotherapy, HT = hyperthermia, LN = lymph node, DOD = died of disease, AWD =alive with disease, NED = no evidence of disease. (Fig. 3) . At the same time, a small area of erythema appeared on her right breast skin. Cytology of the right breast skin revealed tumor cells in the dermis and lymphatic invasion compatible with recurrent breast cancer. Salvage chemotherapy was given with paclitaxel, epirubicin, and trastuzumab, and skin erythema had almost diminished 3 months later. However, bilateral malignant pleural effusion appeared subsequently and the patient died of disease 46 months after mastectomy.
DISCUSSION
The current survey is the first report of multi-institutional experience with ISR. It revealed that ISR after PMRT or BCT is not a common event but approximately 1 of 4 radiation oncologists have some experiences with ISR in the area corresponding to a previous field of postoperative radiotherapy and the estimated incidence was approximately 0.25% of breast cancer patients who had postoperative radiotherapy. ISR exactly demarcating the previously irradiated normal skin area is a rare event but several case reports have been published since 1960'. Most cases were breast cancer patients after PMRT 5, 6) and some cases were other patients including those with nasopharyngeal cancer, endometrial cancer, and cervical cancer. [7] [8] [9] In the breast cancer cases, there is some concern that residual cancer cells are present before radiotherapy. However, the sharp straight line of the ISR area, which matched the radiation field, suggests that radiotherapy was the predominant factor for the occurrence of ISR. ISR corresponding to the previously irradiated area is sometimes difficult to distinguish from acute or chronic radiation dermatitis. 10, 11) The incidences of the inflammatory type of inoperable ipsilateral breast recurrence was reported to be 0.4-6.8% of the cases treated with BCT, and represented 12-32% of all ipsilateral breast recurrences. [12] [13] [14] [15] [16] The prognoses after inflammatory recurrence were very poor and the mean survival period reported was less than 2 years. 14) Some of these earlier cases may have been ISR confined to the area of previous irradiation, however, we could not find any reports that mentioned whether the recurrence matched the irradiated area. Patients after breast conserving surgery without radiotherapy also developed inflammatory recurrence in some reports. 15, 16) However, Nishimura et al. also reported that inflammatory recurrences were more common in those who received radiotherapy (inflammatory: non-inflammatory = 6:3) whereas in those who had not received radiotherapy, non-inflammatory recurrence was more common (18:46). 15) Nishimura et al. suggested that radiation caused lymphatic retention, leading to the formation of tumor emboli in the area where lymphatic fluid was retained. The positive surgical margin and nonradiation therapy which have been shown to be significant risk factors for noninflammatory breast recurrence were entirely unrelated to inflammatory breast recurrence. They reported risk factors related to inflammatory recurrence as positive axillary lymph-nodes metastasis and positive lymphatic invasion. Another study showed the time to inflammatory recurrence was considerably shorter in ER-negative patients compared with ERpositive patients.
16) The current survey also showed high rates of positive axillary lymph-nodes metastases, positive lymphatic invasion, and negative ER status.
In patients after PMRT, inflammatory-type skin recurrence was reported as an impairment to overall survival com- pared to ordinary-type skin recurrence. 17) In the current survey, prognosis of PMRT patients was better than that of BCT patients. One reason for this may be that skin recurrences were the initial solitary site of recurrence in 5 of 8 patients.
18)
The mechanism of ISR confined to the area of previous irradiation has not been clearly understood. Experimental studies in the 1970s and 1980s showed an interesting phenomenon similar to this type of recurrence. Tumor cells injected into experimental animals previously treated with local thoracic irradiation (LTI) generated several times more metastatic nodules in the lungs than when injected into untreated animals. [19] [20] [21] An extensive review of this phenomenon was published by Milas and Peters. 22) They suggested that the enhancement of lung nodule formation in the lung of treated mice could result from local microenvironment changes caused by LTI rather than systemic immunosuppressive effects. Radiation can cause subtle changes in the capillary walls, making it easier for tumor cells to pass into the perivascular connective tissue. 23, 24) The clinical significance of breast cancer recurrence throughout a chest wall that received radiotherapy may be that this results from an effect of lymphatics similar to that described above for lung capillaries.
19) The blockage of the deep dermal lymphatics and lymph-nodes by irradiation may induce cancerous embolus of the dermal lymphatic vessel.
Recent experimental studies revealed that thoracic irradiation caused increased circulating levels of TGF-beta1, as well as lung metastases in the irradiated lung. These effects were blocked by the administration of TGF-beta-neutralizing antibody. These data suggested the increase of lung metastases was at least in part due to a direct effect of TGFbeta on the cancer cells. 25) Another experimental study showed that a sublethal dose of radiation enhances the invasiveness of HCC cells, mainly through matrix metalloproteinase-9 expression mediated by the PI3K/Akt/ NF-kB signal transduction pathway. 26) Some authors speculated that a subcurative dose of radiation promoted the invasiveness of the cancer cells and facilitated the local spread of tumor growth within the irradiated skin. 27) On the other hand, an experimental study showed a dose-response relationship for enhancement of lung colonyforming efficiency by irradiation. 28) In the current survey, ISR had occurred even though patients were treated with 48-50 Gy for the postoperative setting of breast cancer. Fifty Gy is considered to be sufficient for preventing local recurrence in the postoperative state of standard breast cancer, but dermal/sub-dermal dose might be lower than 50 Gy in some cases. However, even if dermal/sub-dermal dose was 50 Gy using bolus or electron beam, it may be insufficient for more aggressive cancer such as multiple lymph-node metastases or intensive lymphatic invasion.
In conclusion, patients who developed ISR tended to have several characteristics including positive lymph-node metastases, intensive lymphatic invasion, and a negative ER status. All cases developed distant metastases subsequently and prognoses were dismal. However, in some patients after PMRT, longer survival was sometimes obtained with salvage therapy. In cases of unusual skin change corresponding to the previously irradiated area after post operative radiotherapy, physicians should also contemplate the diagnosis of ISR next to radiation recall or radiation dermatitis, especially when the aforementioned risk factors are present.
